Zenagene, Inc. is molecular biology company focused on the development of biomarkers to predict cancer risk, in particular for those like lung and pancreatic cancer for which there is no early detection and/or clinical methods for surveillance. In addition, Zenagene is developing agents which reverse the epigenetic silencing of the anticancer gene, Brahma (BRM).
